Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Biotech Catalyst Watch for 2Q10

|Includes:AFFY, APPY, BioCryst Pharmaceuticals, Inc. (BCRX), DCTH, SNTS

Here's a short list of upcoming company milestones we're tracking at Andrew Nava, LLC:

AspenBio Pharma (NASDAQ:APPY)

APPY's AppyScore validation study completed enrollment March 23.  Final results are expected per management within 6-8 weeks of March 23, so approximately the week of May 3 up to including the week of May 17.  APPY's appendicitis diagnostic study was expanded from 600 to 800 patients after they withdrew their old 510K.

Affymax (OTCPK:AFFY)

AFFY and its partner Takeda are expecting top-line results from its pivotal registration study of Hematide in patients with chronic renal failure associated anemia.

Delcath (NASDAQ:DCTH)

DCTH is expecting data this month for its pivotal PHP Melphalan trial in patients with metastatic melanoma.  The primary endpoint is hepatic progression free survival.

Santarus (NASDAQ:SNTS)

SNTS is expecting data 2Q10 from its European study of Budesonide MMX in ulcerative colitis patients. Data from the US study is expected in 2H10.

Biocryst Pharmaceuticals (NASDAQ:BCRX)

BCRX is expecting top-line gout data from its BCX-4208 monotherapy trial.  Results are expected 2Q10.

For more information on the above companies and trials, please visit andrewnava.com. We track over 300 public companies and have over 500 upcoming catalysts across 17 different catalyst types.



Disclosure: No positions

Stocks: BCRX, APPY, AFFY, DCTH, SNTS